Concomitant Chemoradiotherapy in Pyriform Sinus Carcinoma

Jean-Michel Prades, Thierry M. Schmitt, Andrei P. Timoshenko, Pierre-Gilles Simon, Joanne de Cornulier, Marc Durand, Aline Guillot, Christian Martin
2002 Archives of Otolaryngology - Head and Neck Surgery  
Objectives: To test the effectiveness of concurrent chemoradiotherapy in patients with pyriform sinus carcinoma and to demonstrate the feasibility of an organ preservation approach. Design: Clinical trial phase 2. Patients: The study population comprised 46 male patients with resectable stage III and IV pyriform sinus carcinoma. Methods: Two successive chemoradiation regimens were investigated. In protocol 1 (24 patients), carboplatin was given on days 1 through 5 and 28 through 33, with an
more » ... under the curve dose of 5 mg/mL for 1 minute per day and bifractionated radiotherapy (160 rad [1.6 Gy]/fraction) delivered on days 1 through 16 and 28 through 38. A treatment break was planned on days 16 through 27. In protocol 2 (22 patients), chemotherapy was given with the same dose of carboplatin on days 1 and 21, and fluorouracil (750 mg/m 2 per day) on days 1 through 7 and 21 through 28. Radiotherapy with a single fraction of 180 rad (1.8 Gy)/d was delivered during the first 2 weeks and then 150 rad (1.5 Gy) twice a day during the next 3 weeks. Main Outcome Measures: Patients were evaluated for tumor response, toxic reactions, and organ preservation and survival rates. Statistical analysis of disease-free survival and overall survival was performed using the Kaplan-Meier method.
doi:10.1001/archotol.128.4.384 pmid:11926911 fatcat:jo4xsyzzpjempiwxi76piewmzq